Recent developments include multiple quarterly earnings transcripts from Q4 2024 through Q1 2026, and the launch of a new cancer assay, PanTracer Pro, in February 2026. These events highlight ongoing operational updates and product innovation.

• NeoGenomics released its Q1 2026 earnings transcript detailing recent operational and financial results [N1].
• The company also published Q1 2025 and Q2 2025 earnings transcripts providing historical performance context [N2][N3].
• Q4 2024 and Q4 2025 earnings transcripts were released, with Q4 2025 earnings and revenues surpassing estimates [N4][N6][N7].
• NeoGenomics announced the launch of a new cancer assay, PanTracer Pro, in February 2026, expanding its molecular testing portfolio [N8].
• Market commentary noted oversold conditions for NeoGenomics in early 2026, reflecting recent stock price movements [N5].

NeoGenomics benefits from increasing cancer incidence and the growing demand for precision oncology testing, including molecular and MRD assays. Its broad and integrated test menu, including proprietary panels and liquid biopsy technology, positions it to capture diverse clinical and pharmaceutical testing needs. The company's focus on operational efficiency, customer experience, and community oncology market expansion supports sustained relevance. Continued innovation and partnerships may enhance its market presence and service offerings.

NeoGenomics operates in a highly competitive market with larger and specialized competitors that may develop superior or more cost-effective testing solutions. The company has reported net losses and faces risks related to reimbursement, regulatory compliance, and technological obsolescence. Dependence on third-party payers and potential changes in healthcare policy could impact revenue. Execution risks include maintaining rapid turnaround times, integrating acquisitions, and managing operational costs. Intellectual property challenges and market acceptance of new tests also pose risks.

NeoGenomics' competitive strengths include its specialized focus on oncology diagnostics, comprehensive and expanding test menu including proprietary molecular and NGS panels, rapid turnaround times, and integrated consultative services by expert pathologists. Its network of accredited laboratories in the U.S. and U.K., combined with a national direct sales force trained in cancer genetic testing, supports broad market reach. The company's oncology data solutions and pharmaceutical development services further differentiate it by providing integrated support for clinical trials and precision medicine. These factors contribute to a defensible position in a competitive and evolving oncology testing market.

• Competitive Pressure: NeoGenomics faces competition from large national labs, hospital labs, and specialized molecular testing companies with greater resources and capabilities, which may impact market share and pricing.
• Financial Performance: The company has reported net losses, reflecting challenges in achieving profitability amid investments in growth and innovation.
• Regulatory and Reimbursement Risks: Changes in healthcare regulations, payer coverage, and reimbursement policies could adversely affect revenue and operations.
• Technological Obsolescence: Rapid advances in diagnostic technologies require continuous innovation to maintain competitive test offerings and market relevance.
• Operational Execution: Maintaining rapid turnaround times, integrating acquisitions, and managing operational efficiency are critical to sustaining client relationships and growth.

• NeoGenomics, Inc. is a Nevada corporation listed on Nasdaq under ticker NEO [S1].
• The company provides oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation by licensed physicians and molecular experts specializing in pathology and oncology [S1].
• NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom, including CAP-accredited and CLIA-certified labs in multiple U.S. locations and an ISO-certified, CAP-accredited lab in Cambridge, UK [S1].
• Testing services offered include cytogenetics (karyotype analysis), fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular residual disease (MRD) testing, molecular testing including next-generation sequencing (NGS), and morphologic analysis [S1].
• Revenue streams include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, MRD testing, comprehensive technical and professional services, third-party clinical trials and research support, validation laboratory services, and oncology data solutions [S1].
• NeoGenomics offers both technical component (TC) and professional component (PC) services, enabling clients to participate in the diagnostic process according to their capabilities [S1].
• The company is a leading provider of hematologic oncology diagnostic testing and a key provider of solid tumor NGS testing in the U.S. [S1].
• NeoGenomics' molecular test menu includes PanTracer portfolio, Neo Comprehensive panels, and NeoTYPE panels targeting specific cancer types, combining DNA and RNA analysis to detect a broad spectrum of genomic alterations [S1].
• The acquisition of Inivata in June 2021 enhanced capabilities in oncology liquid biopsy technology including RaDaR® for MRD and recurrence detection in plasma samples [S1].
• Pharmaceutical development services support sponsors with laboratory testing, biomarker analysis, data generation, assay development, analytical testing, sample analysis, and data reporting for clinical trials; NeoGenomics does not sponsor or control trials [S1].
• Oncology data solutions involve licensing de-identified data to pharmaceutical and biotech customers for clinical trial patient identification and clinical decision support [S1].
• The company focuses on integrating services to support clinical and pharmaceutical clients, emphasizing connecting patients with therapies and trials [S1].
• Competitive strengths include superior testing technologies, instrumentation, laboratory information systems, client education, domestic and international operations, and rapid turnaround times [S1].
• NeoGenomics has a national direct sales force organized into ten U.S. regions, trained in cancer genetic testing and consultative selling, supported by CRM and laboratory information management systems [S1].
• The company operates under a single reportable segment serving a diverse client base including community pathology and oncology practices, hospital labs, reference labs, academic centers, and pharmaceutical companies [S1].
• For the year ended March 31, 2026, NeoGenomics reported cash and cash equivalents of $146.1 million, current assets of $373.7 million, current liabilities of $84.6 million, resulting in a current ratio of 4.42 and a cash ratio of 1.73 [S2].
• The company reported a net loss of $17.1 million for the quarter ended March 31, 2026 [S2].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
• NeoGenomics' client base is geographically dispersed and diversified; no single client accounted for more than 10% of revenue for the years ended December 31, 2025, 2024, and 2023 [S1].
• Payer mix for 2025 was approximately 71% client direct billing, 16% commercial insurance, and 13% Medicare and other government payers [S1].
• The company maintains professional liability and other insurance policies considered sufficient for current estimated exposures [S1].
• NeoGenomics faces competition from large national labs, hospital labs, in-house physician labs, and specialized molecular testing companies such as Guardant Health, Natera, Exact Sciences, Caris Life Science, Tempus AI, and Myriad Genetics [S1].
• The company emphasizes improving turnaround times, expanding test menus including proprietary tests, and enhancing post-test consultation services to gain market share [S1].
• Recent news includes multiple earnings call transcripts for Q1 2026, Q1 2025, Q2 2025, Q4 2024, and Q4 2025, as well as the launch of a new cancer assay PanTracer Pro in February 2026 [N1][N2][N3][N4][N6][N7][N8].
• NeoGenomics' strategic focus for 2026 includes sustaining culture, growing through targeted innovation, extending market relevance in therapy selection and MRD, expanding community oncology market presence, improving operational efficiency, and enhancing customer experience [S1].